TY -的T1 -确定癫痫中额外的效用天监测单元(EMU)对病人没有在入学前5天(p3.5 - 026) JF -神经学乔-神经学六世- 92 - 15补充SP - p3.5 - 026 AU -作为Cherayil AU - Pouya Khankhanian AU -迈克尔·盖尔芬德Y1 - 2019/04/09 UR - 首页//www.ez-admanager.com/content/92/15_supplement/p3.5 - 026. -抽象N2 -目的:识别特征预测non-diagnostic入学的鉴别诊断/分类EMU病人没有事件的前5天入院。背景:以证据为基础的指导有限关于适当的时机出院EMU。特别是,它是未知的,患者没有成功的早期诊断承认可能会受益于持续监测。设计/方法:我们进行了回顾性的图表总结的鸸鹋住院的病人之间的宾夕法尼亚大学的1/2012和7/2017。卡方测试和逻辑回归模型被用来研究各种各样的病人,是否结合脑电图和成像特征可以独立或预测如果病人会有non-diagnostic留下来。Results: We identified 198 patients with EMU length of stay >5 days without events in first five days of admission out of a total of approximately 1400 EMU admissions over a five year period. Absence of interictal discharges in the first 5 days was associated with non-diagnostic stay (p =.0009, OR = 2.90). Lack of motor semiology was also associated with non-diagnostic stay (p =.0267, OR = 2.36). The absence of both interictal discharges and major motor semiology had a positive predictive value of 82.8% for non-diagnostic admission. Demographic factors, lesional MRI, and number and type of AEDs did not influence likelihood of diagnostic or non-diagnostic stay.Conclusions: Non-motor semiology and the absence of interictal discharges predict non-diagnostic admission in patients admitted to the EMU for >5 days. These criteria may identify patients unlikely to benefit from prolonged EMU admission and thereby facilitate earlier discharge and improved EMU utilization.Disclosure: Dr. Cherayil has nothing to disclose. Dr. Khankhanian has nothing to disclose. Dr. Gelfand has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Guidepoint. Dr. Gelfand has received research support from Aquestive, Biogen Idec, Eisai Inc., Epilepsy Foundation, Engage Therapeutics, Pfizer Inc., SK, and UCB Pharma. ER -